Renal Medullary Carcinoma

9 clinical trials · Condition

Record	Firm	Date
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma (NCT06302569)	Giuseppe Procopio	2025-05-30
Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies (NCT06444880)	M.D. Anderson Cancer Center	2024-10-09
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C... (NCT06161532)	National Cancer Institute (NCI)	2024-08-01
Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla (NCT05347212)	M.D. Anderson Cancer Center	2022-09-22
Effects of Itraconazole and Rifampin on the Blood Tazemetostat Levels (NCT04537715)	Epizyme, Inc.	2020-04-23
A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study (NCT02875548)	Epizyme, Inc.	2016-08-30
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma (NCT02601950)	Epizyme, Inc.	2015-12-22
Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer (NCT00027820)	Fred Hutchinson Cancer Center	2001-08-01
Tazemetostat Expanded Access Program for Adults With Solid Tumors (NCT03874455)	Epizyme, Inc.

Every clearance here is in the API, with alerts when new ones post.